Abstract Number: 637 • 2017 ACR/ARHP Annual Meeting
The Effect of Biologic Therapies on the Gut Microbial Composition in Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis affecting multiple clinical domains. If left untreated, it has the potential for significant morbidity and disability.…Abstract Number: 638 • 2017 ACR/ARHP Annual Meeting
Are There Clinical Demographic or Subclinical Ultrasonographic Data That Can Predict Flare in Psoriatic Arthritis Patients during a Phase of Minimal Disease Activity after Spacing of Anti-TNF Blockers Injections?
Background/Purpose: Tumour necrosis factor (TNF)-blocker tapering has been proposed for patients with psoriatic arthritis (PA) in clinical remission. To evaluate if there are clinical, demographic…Abstract Number: 639 • 2017 ACR/ARHP Annual Meeting
Clinical and Sonographic Analysis of Patients with Psoriasis without Musculoskeletal Complaints. Preeliminary Results of a Prospective Study: The PRE-Psa Cohort
Background/Purpose: Early diagnosis in psoriatic arthritis (PsA) is mandatory in order to initiate early therapy and prevent disability. Around 20% of patients with Psoriasis (PsO)…Abstract Number: 640 • 2017 ACR/ARHP Annual Meeting
Is There a Relationship between Spondyloarthritis and Periodontitis? a Case-Control Study
Background/Purpose: Knowledge of the existence of an epidemiological association between SpA and periodontitis may fuel pathophysiological thinking about SpA and if established, have clinical implications.…Abstract Number: 641 • 2017 ACR/ARHP Annual Meeting
Children with Treatment-Naive Enthesitis-Related Arthritis Have Decreased Fecal Abundance of Faecalibacterium Prausnitzii A2-165 and Bacteroides Fragilis: A Multi-Center Collaborative Study
Background/Purpose: Prior studies have demonstrated abnormalities in the composition of the gastrointestinal microbiota in pediatric and adult patients with spondyloarthritis (SpA.) In particular, diminished fecal…Abstract Number: 642 • 2017 ACR/ARHP Annual Meeting
Downstream Effects of Apremilast in Human Arthritic Ex Vivo Models
Background/Purpose: Apremilast (Otezla) is a PDE4 inhibitor approved for the treatment of psoriasis and psoriatic arthritis, but the mechanisms of action of apremilast are not…Abstract Number: 643 • 2017 ACR/ARHP Annual Meeting
Mir-10b-5p Is a IL-22 Regulator in CD4+T Cells from Ankylosing Spondylitis
Background/Purpose: Emerging data suggest that a single microRNA (miR) can profoundly alter the phenotype and outcome of immune responses, offering the prospect of therapeutic use.…Abstract Number: 644 • 2017 ACR/ARHP Annual Meeting
Association of Osteonectin, Osteopontin and Osteocalcin with Inflammation and Cardiovascular Risk in Patients with Axial Spondyloarthritis
Background/Purpose: A higher incidence of cardiovascular (CV) risk factors and atherosclerosis has been reported in axial spondyloarthritis (axSpA) patients1. Since axSpA (particularly AS) is an…Abstract Number: 645 • 2017 ACR/ARHP Annual Meeting
An Oral Tyk2 Inhibitor Effectively Suppresses the Development of Murine Th17 Cells In Vivo and Prevents Joint Damage in Experimental Ankylosing Spondylitis
Background/Purpose: Th17 cells play an important role in the pathogenesis of ankylosing spondylitis (AS). Tyk2, a member of the Janus Kinase (JAK) family of signaling…Abstract Number: 646 • 2017 ACR/ARHP Annual Meeting
Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Is a Susceptibility Factor for Early Axial Spa Meeting the ASAS Classification Criteria: Results from the Spondyloarthritis Caught Early and DEvenir des Spondyloarthrites Indifférenciées Récentes Cohorts
Background/Purpose: Genetic research in axSpA is performed in patients with longstanding ankylosing spondylitis (AS). Early axial spondyloarthritis (axSpA) is a diverse patient group in which…Abstract Number: 647 • 2017 ACR/ARHP Annual Meeting
Gene Expression in Cellular Subsets in Psoriatic Disease
Background/Purpose: Psoriatic arthritis is an inflammatory musculoskeletal disease which develops in 30% of patients with psoriasis. Our previous peripheral blood microarray study identified CXCL10, NOTCH2NL,…Abstract Number: 648 • 2017 ACR/ARHP Annual Meeting
Are Choline Metabolites Associated with Inflammation in Psoriatic Arthritis?
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory disease affecting the joints and connective tissue and is associated with psoriasis of the skin and nails. In…Abstract Number: 649 • 2017 ACR/ARHP Annual Meeting
Role of Eicosanoids As Biomarkers in Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory disease affecting the joints and connective tissue and is associated with psoriasis of the skin and nails. There…Abstract Number: 650 • 2017 ACR/ARHP Annual Meeting
Genome-Wide DNA Methylation, Transcriptomics, and Proteomics of Psoriasis and Psoriatic Arthritis in Monozygotic Twins
Background/Purpose: Psoriatic disease is a chronic inflammatory disorder spanning from skin disease (PsO) to psoriatic arthritis (PsA) without known serum biomarkers. The genetic background is…Abstract Number: 651 • 2017 ACR/ARHP Annual Meeting
Role of Mir-21-5p As a Potential Biomarker of Psoriatic Arthritis and Response to Treatment
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in patients with psoriasis. miRNA’s are small non coding RNAs whose main function, at a post…